We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
04/10/2016 14:02 | There seems to be some notion on the BB's that Summit trading is halted on NASDAQ opening due to demand .. need to verify. | hugus maximus | |
04/10/2016 13:59 | £3+ when Nasdaq opens!! | miahkaysor | |
04/10/2016 13:56 | For those that are just looking in, if you can get hold of the Wainwright note a couple of weeks ago, it will give you an idea (they had a 1yr price target of $26 and that was before todays news). Ridinazole (our phase 3 ready antibiotic against Cdiff) is slated to have close to $1bn in revenues post trials and approval. (slated as 2021) Edit: they also have earnings per share by 2025 of £7.70. ETZ and the company are now fully funded till after we get then key results of the next DMD trial and potential approval (although if the results are stellar, still think they could go for it in 2017). Excellent that we share all costs 55/45 but have kept US rights. | waterloo01 | |
04/10/2016 13:53 | Only just logged in and seen the News. As I predicted "insurance" for Sarepta. My view is that this remains a long term investment. I put a value on Summit along Wainwrights lines, a long way still to go | freedosh | |
04/10/2016 13:49 | $15 pre opening | colin12345678 | |
04/10/2016 13:43 | Fundies all over the call. | waterloo01 | |
04/10/2016 13:41 | At last. Been waiting so many years for this to look more solid ! | artrade | |
04/10/2016 13:40 | Football, yes and he's been very adult about it. | waterloo01 | |
04/10/2016 13:38 | Anyone seen pat? | football | |
04/10/2016 13:37 | Damn, only just tuned in today and seems I've missed all the action. | anusol | |
04/10/2016 13:34 | I bet c-diff deal now comes out this week. | sorrento06 | |
04/10/2016 13:29 | It adds up to $842 million. And Sarepta also agreed to share R&D expenses in the deal. | waterloo01 | |
04/10/2016 13:28 | Sarepta valued at $3.2bn. Their DMD drug will only treat 16% of the patients. SUMM valued at £130m Their DMD drug will treat 100% of the patients. | someuwin | |
04/10/2016 13:25 | Nasdaq halted boom boom | colin12345678 | |
04/10/2016 13:22 | Nope still live call in to listen Just call in on 02034271918, | colin12345678 | |
04/10/2016 13:21 | how many are free float?? anyone? | miahkaysor | |
04/10/2016 13:21 | Serepta Interested in another drug But these guys don't want to tie up yet. | colin12345678 | |
04/10/2016 13:20 | Big buy in the background! | sorrento06 | |
04/10/2016 13:18 | is conference call over? | pre | |
04/10/2016 13:17 | Neo, on this alone 10% could be a few $100m a year, plus US sales. Plus Becker (which is a much larger population) | waterloo01 | |
04/10/2016 13:17 | Is this what they call momentum?!----can't wait for a bit of Nasdaq action | shearluc | |
04/10/2016 13:16 | She's asked what will they be presenting at world muscle this week and he said there is a SEPARATE ANNOUNCEMENT all Americans asking the questions | colin12345678 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions